Tularemia;Tularémie

EMC - Maladies Infectieuses

Volumn 2, Issue 1, 2005, Pages 1-10

  Guihot, A ^a   Bricaire, F ^a   Bossi, P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Francisella tularensis; Tularemia; Zoonosis

Indexed keywords

EID: 32644433795     PISSN: 1638623X     EISSN: 1638623X     Source Type: Journal    
DOI: 10.1016/j.emcmi.2004.10.002     Document Type: Short Survey

References (32)

1. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev 2002;15:631-46.
2. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285:2763-73.
3. Bossi P, Bricaire F. La tularémie: arme potentielle du bioterrorisme. Presse Méd 2003;32:1123-7.
4. Bossi P, Baka A, Tegnell A, Hendriks J, Werner A, Maidhof H, et al. European guidelines for the clinical management of tularemia and bioterrorism-related tularemia. Euro Surveill. 2004 (sous presse).
5. McCoy G. A plaque-like disease in rodents. Public Health Bull 1911;43:53-71.
6. McCoy G, Chapin S. Further observations on a plague-like disease of rodents with a preliminary note on the causative agent. J Infect Dis 1912;10:61-72.
7. Wheery W, Lamb B. Infection of man with Bacterium tularense. J Infect Dis 1914;15:331-40.
8. Francis E. Tularemia. JAMA 1925;250:3216-24.
9. Lamps LW, Havens JM, Sjostedt A, Page DL, Scott MA. Histologic and molecular diagnosis of tularemia: a potential bioterrorism agent endemic to North America. Mod Pathol 2004;17:489-95.
10. Haristoy X, Lozniewski A, Tram C, Simeon D, Bevanger L, Lion C. Francisella tularensis bacteremia. J Clin Microbiol 2003;41:2774-6.
11. Sjostedt A. Virulence determinants and protective antigens of Francisella tularensis. Curr Opin Microbiol 2003;6:66-71.
12. Eliasson H, Lindback J, Nuorti JP, Arneborn M, Giesecke J, Tegnell A. The 2000 tularemia outbreak: a case-control study of risk factors in disease-endemic and emergent areas, Sweden. Emerg Infect Dis 2002;8:956-60.
13. Reintjes R, Dedushaj I, Gjini A, Jorgensen TR, Cotter B, Lieftucht A, et al. Tularemia outbreak investigation in Kosovo: case control and environmental studies. Emerg Infect Dis 2002;8:69-73.
14. Evans M, Gregory D, Schaffner W, McGee Z. Tularemia: a 30-year experience with 88 cases. Medicine 1985;64:251-69.
15. Feldman KA, Enscore RE, Lathrop SL, Matyas BT, McGuill M, Schriefer ME, et al. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med 2001;345:1601-6.
16. Gill V, Cunha B. Tularemia pneumonia. Semin Respir Infect 1997;12:61-7.
17. Lovell V, Cho C, Lndsey N, Nelson P. Francisella tularensis meningitis: a rare clinical entity. J Infect Dis 1986;154:916-8.
18. Adams C. Tularemic pericarditis. Dis Chest 1958;34:1-8.
19. Kleibl K. Les tularémides: érythèmes polymorphes et érythèmes noueux tularémiques. Med Mal Infect 1971;11:447-51.
20. Shapiro DS, Schwartz D. Exposure of laboratory workers to Francisella tularensis despite a bioterrorism procedure. J Clin Microbiol 2002;40:2278-81.
21. Johansson A, Berglund L, Eriksson U, Goransson I, Wollin R, Forsman M, et al. Evaluation of PCR-based methods for discrimanation of Francisella species and subspecies and development of a specific PCR that distinguishes the two major subspecies of Francisella tularensis. J Clin Microbiol 2000;38:4180-5.
22. Afssaps. Fiche Afssaps: tularémie. http://agmed.sante. gouv.fr/htm/10/biotox/tularemi.pdf. Version 3 du 08/11/01.
23. INVS. Guide pour l'investigation épidémiologique. Institut de veille sanitaire. Tularémie. http://www.invs.sante.fr. Mise à jour du 14/11/01.
24. Enderlin G, Morales L, Jacobs R, Cross J. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994;19:42-7.
25. Edson R, Terrell C. The aminoglycosides. Mayo Clin Proc 1999;74:519-28.
26. Limaye A, Hooper C. Treatment of tularemia with fluoroquinolone: two cases and review. Clin Infect Dis 1999;29:922-4.
27. The European Agency for the Evaluation of Medicinal Products/CPMP guidance document on use of medicinal products for treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism. Juillet 2002. www.emea.eu.int.
28. Elkins K, Cowley S, Bosio C. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect 2003;5:135-42.
29. DGS, Circulaire n2002-492 du 20 septembre 2002 relative à la transmission obligatoire de données individuelles à l'autorité sanitaire en cas de tularémie. Bulletin officiel n 2002-41.
30. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399-411.
31. Hornick R. Tularemia revisited. N Engl J Med 2001;345:1637-9.
32. In: Health aspects of chemical and biological weapons. Geneva: World Health Organization; 1970. p. 105-7.